Advertisement

Cancer Immunology, Immunotherapy

, Volume 66, Issue 6, pp 811–818 | Cite as

The Summit for Cancer Immunotherapy (Summit4CI), June 26–29, 2016 Halifax, Canada

  • Maartje C. A. Wouters
  • Céline M. Laumont
  • Branson Chen
  • Seong Jun Han
  • Kathy Matuszewska
  • Kyle Potts
  • Jeanette E. Boudreau
  • Connie. M. Krawczyk
Meeting Report

Introduction

In June 2016, the Canadian Cancer Immunotherapy Consortium (CCIC), an association dedicated to the scientific advancement of immunotherapy for cancer, partnered with BioCanRx, a Network of Centre of Excellence program focused on biotherapeutics for cancer treatment, to hold the Summit for Cancer Immunotherapy (Summit4CI) in Halifax, Canada. The synergy of these two organizations—both highly active in the field of cancer biotherapy and supported by the Government of Canada—offered a unique opportunity for multidisciplinary discussions and trainee events. Bringing together researchers, trainees, policy makers, patients, physicians, advocates, and industry partners, this unique event presented a holistic perspective on the past, present, and future of cancer immunotherapy, considering how scientific and logistical advances will translate cutting-edge research into novel therapeutics.

Training of highly qualified personnel was a theme and focus throughout the meeting. To...

Keywords

Cancer Immunotherapy Oncolytic virus Tumor microenvironment Precision medicine Cancer genetics 

Abbreviations

CAR

Chimeric antigen receptor

CCIC

Canadian Cancer Immunotherapy Consortium

CRISPR

Clustered regularly interspaced short palindromic repeats

CTLA4

Cytotoxic T lymphocyte-associated protein-4

DC

Dendritic cell

FZD5

Frizzled class receptor 5

HER2

Human epidermal growth factor receptor-2

IFN

Interferon

IL

Interleukin

IRE-1

Inositol-requiring enzyme-1

MEK

Mitogen-activated protein kinase

MHC

Major histocompatibility complex

NK

Natural killer

NKT

Natural killer T

PD-1

Programmed cell death protein-1

PD-L

Programmed death ligand

RAS

RAS-type GTPase family

RGMb

Repulsive guidance molecule b

RNF43

Ring finger protein 43

TAC

T cell antigen coupler

TEX

Tumor-derived exosomes

TIL

Tumor-infiltrating lymphocytes

TIM-3

T cell immunoglobulin and mucin domain 3

TME

Tumor microenvironment

T-Vec

Talimogene laherparepvec

VSV

Vesicular stomatitis virus

XBP1

X-box binding protein-1

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest. Connie Krawczyk participated in the organization of this meeting as coordinator of knowledge dissemination and outreach.

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Maartje C. A. Wouters
    • 1
  • Céline M. Laumont
    • 2
  • Branson Chen
    • 3
  • Seong Jun Han
    • 4
    • 9
  • Kathy Matuszewska
    • 5
  • Kyle Potts
    • 6
  • Jeanette E. Boudreau
    • 7
  • Connie. M. Krawczyk
    • 8
  1. 1.Deeley Research CentreBritish Columbia Cancer AgencyVictoriaCanada
  2. 2.Institute for Research in Immunology and CancerUniversité de MontréalMontrealCanada
  3. 3.Department of Laboratory Medicine and Pathobiology, Toronto General Research InstituteUniversity of TorontoTorontoCanada
  4. 4.Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer CentreUniversity Health NetworkTorontoCanada
  5. 5.Department of Biomedical SciencesUniversity of GuelphGuelphCanada
  6. 6.Department of Oncology, Faculty of Medicine and Dentistry, Cancer Research Institute of Northern Alberta (CRINA)University of AlbertaEdmontonCanada
  7. 7.Departments of Pathology and Microbiology & ImmunologyDalhousie UniversityHalifaxCanada
  8. 8.Departments of Microbiology and Immunology and PhysiologyGoodman Cancer Research CenterMontrealCanada
  9. 9.Department of ImmunologyUniversity of TorontoTorontoCanada

Personalised recommendations